BIO-TECHNE'S ADVANCED CELL DIAGNOSTICS (ACD) SETS NEW STANDARD IN SPATIAL BIOLOGY WITH PROTEASE-FREE RNASCOPE MULTIOMICS

Rhea-AI Summary

Bio-Techne's Advanced Cell Diagnostics (ACD) achieves a technical breakthrough with the development of a protease-free RNAscope spatial multiomics workflow, enabling same-slide detection of protein and RNA biomarkers with unparalleled sensitivity and tissue morphology. The new innovation allows for simultaneous imaging of both RNA and protein biomarkers on the same tissue section, providing an unprecedented single-cell view of disease pathology and therapeutic response. The advanced workflow preserves protein and RNA integrity, simplifies image and data analysis, and will be showcased at the Advances in Genome Biology and Technology (AGBT) 2024 General Meeting.

Insights

Biotechnology Analyst

The announcement by Bio-Techne Corporation represents a significant technological advancement within the field of spatial biology. The development of a protease-free RNAscope workflow facilitates the simultaneous detection of both protein and RNA biomarkers on the same tissue slide, which is a notable enhancement over existing methods that often compromise the integrity of one biomarker type in favor of another. This breakthrough could have profound implications for the precision and accuracy of biomarker analysis in research and clinical settings.

From a biotechnology perspective, the ability to preserve both RNA and protein integrity during analysis is crucial. It allows for more accurate profiling of disease states and can significantly aid in the development of targeted therapies. The integration of this technology into Bio-Techne's multiomics application on Lunaphore's COMET platform underscores the potential for this innovation to streamline multiomic data acquisition and analysis, which is essential for advancing personalized medicine.

Moreover, the positive customer feedback and the integration of this workflow into the existing RNAscope portfolio suggest a strong market demand for this enhanced capability. This could translate into increased adoption rates of Bio-Techne's technology, potentially leading to revenue growth and a more robust competitive position in the spatial biology market.

Market Research Analyst

The spatial biology sector is rapidly evolving and advancements such as the protease-free RNAscope workflow are indicative of the industry's trajectory towards more sophisticated and integrated multiomic analysis. Bio-Techne's innovation could catalyze further growth in this market segment and influence the strategies of competitors and new entrants alike.

Considering the existing market footprint of RNAscope technology, with over 9,500 peer-reviewed publications and a substantial number of unique probes sold, this new development could further entrench Bio-Techne's ACD brand as a leader in the field. The potential for this technology to be adopted in clinical applications could also open up new revenue streams and partnerships, particularly as precision medicine becomes more prevalent.

Investors and stakeholders should monitor the adoption rate of this new workflow and its impact on Bio-Techne's financial performance. The upcoming data presentations at the AGBT 2024 General Meeting will be critical in demonstrating the efficacy and utility of the technology, which may influence market sentiment and Bio-Techne's stock valuation.

Medical Research Analyst

The technical breakthrough achieved by Bio-Techne's ACD brand has the potential to revolutionize the field of pathological analysis and disease understanding. The protease-free RNAscope workflow's ability to maintain tissue morphology while detecting multiple biomarkers could enhance the resolution of single-cell analyses. This is particularly relevant for complex diseases like cancer, where the tumor-immune microenvironment plays a crucial role in disease progression and response to therapy.

By enabling a more comprehensive view of gene expression and biomarker distribution within a single tissue section, researchers can gain a deeper understanding of disease mechanisms at the molecular level. This could lead to the identification of new therapeutic targets and the development of more effective treatment strategies. The upcoming presentation of data related to the tumor-immune microenvironment of bladder cancer patients at AGBT could provide valuable insights into the practical applications of this technology in a clinical research setting.

Advanced Cell Diagnostics (ACD), a Bio-Techne spatial biology brand, achieves technical breakthrough enabling protease-free, same-slide detection of protein and RNA biomarkers using industry-leading RNAscope™ technology.

MINNEAPOLIS, Jan. 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), a Bio-Techne spatial biology brand, has set a new standard with the development of a next-generation, protease-free RNAscope spatial multiomics workflow. Optimized for same-slide detection of protein and RNA biomarkers with unparalleled sensitivity and tissue morphology, the newly developed RNAscope spatial multiomics workflow is compatible with both manual and automated assays. ACD's novel protease-free RNAscope workflow is incorporated in Bio-Techne's recently announced best-in-class multiomics application on Lunaphore's COMET platform.

Simultaneous imaging of both RNA and protein biomarkers on the same tissue section will provide an unprecedented single-cell view of disease pathology and therapeutic response. ACD's new innovation marks a significant improvement over existing spatial technologies which are designed for the detection of either RNA or protein, not both, and typically lead to the degradation of the alternate biomarker type.

By eliminating the need for proteases often used in RNA detection, this advanced workflow preserves protein and RNA integrity and conserves tissue morphology. With this advancement, subcellular gene expression and multiomic changes can be easily quantified and image and data analysis are further simplified.

"We are proud to achieve another milestone in our spatial multiomics strategy with the development of a novel, protease-free RNAscope workflow," said Kim Kelderman, Bio-Techne's Chief Operating Officer. "We have been impressed by the overwhelmingly positive response received from customers who have tested this new workflow with our current on-market RNAscope assays, and we look forward to offering this new capability across our RNAscope portfolio this year."

Bio-Techne's ACD brand is a pioneer in spatial biology, delivering industry-leading single-molecule sensitivity and unrivaled specificity with its patented RNAscope ISH technology for over 10 years. With over 9,500 peer reviewed publications and over 50,000 unique probes sold, RNAscope technology has enabled the spatial detection of the widest range of RNA subtypes in the industry from research to clinical applications.

Data will be showcased in a series of activities at the Lunaphore Suite, Curacao 4 at the Advances in Genome Biology and Technology (AGBT) 2024 General Meeting in Orlando Florida on February 5-8. Additional data demonstrating technical advances in the codetection of RNA with both proteins and protein-protein interactions using RNAscope will be presented at AGBT by ACD scientist Ge-Ah Kim, Ph.D. on Feb 7 at poster #633 titled "Single-slide, in situ multiomic imaging of mRNA, protein and protein-protein interactions in the tumor-immune microenvironment of bladder cancer patients."

About Bio-Techne Corporation

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated over $1.1 billion in net sales in fiscal 2023 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.

Bio-Techne Investor Contact:
David Clair,
Vice President, Investor Relations and Corporate Development
612-656-4416
David.clair@bio-techne.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-technes-advanced-cell-diagnostics-acd-sets-new-standard-in-spatial-biology-with-protease-free-rnascope-multiomics-302046066.html

SOURCE Bio-Techne Corporation

FAQ

What is the technical breakthrough achieved by Advanced Cell Diagnostics (ACD)?

ACD has achieved a technical breakthrough with the development of a protease-free RNAscope spatial multiomics workflow, enabling same-slide detection of protein and RNA biomarkers with unparalleled sensitivity and tissue morphology.

What is the significance of the new RNAscope spatial multiomics workflow?

The new innovation allows for simultaneous imaging of both RNA and protein biomarkers on the same tissue section, providing an unprecedented single-cell view of disease pathology and therapeutic response.

Where will the data showcasing the technical advances be presented?

The data will be showcased at the Advances in Genome Biology and Technology (AGBT) 2024 General Meeting in Orlando, Florida at the Lunaphore Suite, Curacao 4.